Hjem
Halfdan Sørbyes bilde

Halfdan Sørbye

Professor
  • E-postHalfdan.Sorbye@uib.no
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) (2022). Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas. The Oncologist. 299-306.
  • Vis forfatter(e) (2022). Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer. Cancer Treatment and Research Communications.
  • Vis forfatter(e) (2022). Prognostic role of tumour infiltrating lymphocytes and macrophages in relation to tumour MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients. British Journal of Cancer. 48-56.
  • Vis forfatter(e) (2022). KRAS-G12C mutation in one real-life and three population-based Nordic cohorts of metastatic colorectal cancer. Frontiers in Oncology. 1-11.
  • Vis forfatter(e) (2022). Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study. ESMO Open.
  • Vis forfatter(e) (2021). Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Gut. 1768-1781.
  • Vis forfatter(e) (2021). The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocrine-Related Cancer. 1-14.
  • Vis forfatter(e) (2021). Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms. Journal of neuroendocrinology. 1-12.
  • Vis forfatter(e) (2021). Quality of life in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy—the randomized NORDIC9-study. Cancers. 16 sider.
  • Vis forfatter(e) (2021). Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncologica. 931-941.
  • Vis forfatter(e) (2021). Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients. British Journal of Cancer.
  • Vis forfatter(e) (2021). Feminizing adrenal tumor identified by plasma steroid profiling. Endocrinology, Diabetes and Metabolism Case Reports. 1-5.
  • Vis forfatter(e) (2021). ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. Journal of neuroendocrinology. 1-10.
  • Vis forfatter(e) (2021). Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer. International Journal of Cancer. 1385-1397.
  • Vis forfatter(e) (2020). Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors. Neuroendocrinology. 217-224.
  • Vis forfatter(e) (2020). Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours. Health and Quality of Life Outcomes. 1-11.
  • Vis forfatter(e) (2020). PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. PLOS ONE. 1-12.
  • Vis forfatter(e) (2020). Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. Acta Oncologica. 417-426.
  • Vis forfatter(e) (2020). Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3. Scientific Reports. 1-9.
  • Vis forfatter(e) (2020). CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup . Frontiers in Oncology. 1-11.
  • Vis forfatter(e) (2020). A plasma protein biomarker strategy for detection of small intestinal neuroendocrine tumors. Neuroendocrinology.
  • Vis forfatter(e) (2020). A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. Neuroendocrinology. 883-894.
  • Vis forfatter(e) (2019). Unmet needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Neuroendocrinology. 54-62.
  • Vis forfatter(e) (2019). Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. Annals of Oncology. 1088-1095.
  • Vis forfatter(e) (2019). Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach. European Journal of Health Economics. 1-14.
  • Vis forfatter(e) (2019). Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. The Lancet Gastroenterology and Hepatology. 376-388.
  • Vis forfatter(e) (2019). Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: A multicenter cohort study. Endocrine-Related Cancer. 227-239.
  • Vis forfatter(e) (2019). Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study. Acta Oncologica. 1-8.
  • Vis forfatter(e) (2019). Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients. Cancer Medicine. 3623-3635.
  • Vis forfatter(e) (2018). The problem of high-grade gastroenteropancreatic neuroendocrine neoplasms: Well-differentiated neuroendocrine tumors, neuroendocrine carcinomas, and beyond. Endocrinology and metabolism clinics of North America (Print). 683-698.
  • Vis forfatter(e) (2018). Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. British Journal of Cancer. 1609-1616.
  • Vis forfatter(e) (2018). Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Medical Oncology (MO).
  • Vis forfatter(e) (2018). Cost-effectiveness of liver transplantation in patients with colorectal metastases confined to the liver. British Journal of Surgery.
  • Vis forfatter(e) (2018). Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer. 35-45.
  • Vis forfatter(e) (2018). Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer. 807-815.
  • Vis forfatter(e) (2017). Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer. Virchows Archiv. 1-11.
  • Vis forfatter(e) (2017). Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. European Journal of Surgical Oncology. 1682-1689.
  • Vis forfatter(e) (2017). Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. BMC Cancer.
  • Vis forfatter(e) (2017). Population-based study on resection rates and survival in patients with colorectal liver metastasis in Norway. British Journal of Surgery. 580-589.
  • Vis forfatter(e) (2017). Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial. BMC Surgery.
  • Vis forfatter(e) (2017). High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. PLOS ONE. 1-13.
  • Vis forfatter(e) (2017). Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. European Journal of Cancer. 26-35.
  • Vis forfatter(e) (2017). Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. PLOS ONE. 1-15.
  • Vis forfatter(e) (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology-Diagnosis and Prognostic Stratification. Neuroendocrinology. 196-200.
  • Vis forfatter(e) (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Chemotherapy. Neuroendocrinology. 281-294.
  • Vis forfatter(e) (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Biotherapy and Novel Targeted Agents. Neuroendocrinology. 266-280.
  • Vis forfatter(e) (2017). Cetuximab in treatment of metastatic colorectal cancer: Final survival analyses and extended RAS data from the NORDIC-VII study. British Journal of Cancer. 1271-1278.
  • Vis forfatter(e) (2017). A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors. Endocrine-Related Cancer. 427-443.
  • Vis forfatter(e) (2016). TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer. OncoTarget. 59441-59457.
  • Vis forfatter(e) (2016). Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer. OncoTarget. 41948-41958.
  • Vis forfatter(e) (2016). Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study. Annals of Surgical Oncology. 1721-1728.
  • Vis forfatter(e) (2016). Intra-patient inter-metastatic genetic heterogeneity in colorectal cancer as a key determinant of survival after curative liver resection. PLoS Genetics. 22 sider.
  • Vis forfatter(e) (2016). Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. OncoTarget. 75013-75022.
  • Vis forfatter(e) (2016). Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. International Journal of Cancer. 647-656.
  • Vis forfatter(e) (2016). Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review. Acta Oncologica. 881-885.
  • Vis forfatter(e) (2016). ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 186-194.
  • Vis forfatter(e) (2016). Drug costs and benefits of medical treatments in high-unmet need solid tumours in the Nordic countries. Journal of Cancer Policy. 12-22.
  • Vis forfatter(e) (2016). A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. Journal of Controlled Release. 172-181.
  • Vis forfatter(e) (2015). Review on adjuvant chemotherapy for rectal cancer-why do treatment guidelines differ so much? Acta Oncologica. 437-446.
  • Vis forfatter(e) (2015). Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. European Journal of Cancer. 2708-2717.
  • Vis forfatter(e) (2015). Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases. World Journal of Surgical Oncology (WJSO).
  • Vis forfatter(e) (2015). Modeling and Validating the Cost and Clinical Pathway of Colorectal Cancer. Medical decision making. 255-265.
  • Vis forfatter(e) (2015). Maintenance therapy with cetuximab every second week in the first-line treatment of metastatic colorectal cancer: the NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group. Clinical colorectal cancer. 170-176.
  • Vis forfatter(e) (2015). Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. International Journal of Cancer. 2470-2477.
  • Vis forfatter(e) (2015). High BRAF mutation frequency and marked survival differences in subgroups according to KRAS/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort. PLOS ONE.
  • Vis forfatter(e) (2014). Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: Results from the NORDIC VII Study. PLOS ONE.
  • Vis forfatter(e) (2014). Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncologica. 1284-1297.
  • Vis forfatter(e) (2014). Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. European Journal of Cancer. 912-919.
  • Vis forfatter(e) (2013). Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Annals of Oncology. 152-160.
  • Vis forfatter(e) (2013). Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. The Lancet Oncology. 1208-1215.
  • Vis forfatter(e) (2013). Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. Annals of Oncology. 2354-2360.
  • Vis forfatter(e) (2012). Small Cell Lung Cancer in a 14-Year-Old Girl. Journal of Pediatric Hematology/Oncology. E86-E88.
  • Vis forfatter(e) (2012). Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983). Annals of Surgery. 534-539.
  • Vis forfatter(e) (2012). Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII Study. Journal of Clinical Oncology. 1755-1762.
  • Vis forfatter(e) (2012). Lower treatment intensity and poorer survival in metastatic colorectal cancer patients who live alone. British Journal of Cancer. 189-194.
  • Vis forfatter(e) (2012). Let-7 miRNA-binding site polymorphism in the KRAS 3 ' UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab. BMC Cancer.
  • Vis forfatter(e) (2012). Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. British Journal of Cancer. 435-441.
  • Vis forfatter(e) (2012). Combination Chemotherapy in Advanced Adrenocortical Carcinoma. New England Journal of Medicine. 2189-2197.
  • Vis forfatter(e) (2011). Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. The Pharmacogenomics Journal. 61-71.
  • Vis forfatter(e) (2011). Clinical effect of Temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 4617-4622.
  • Vis forfatter(e) (2010). Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncologica. 740-756.
  • Vis forfatter(e) (2009). Clinical Trial Enrollment, Patient Characteristics, and Survival Differences in Prospectively Registered Metastatic Colorectal Cancer Patients. Cancer. 4679-4687.
  • Vis forfatter(e) (2008). Prognostic clinical factors in metastatic colorectal cancer. Advances in Gastrointestinal Cancers. 6-8.
  • Vis forfatter(e) (2008). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. The Lancet. 1007-1016.
  • Vis forfatter(e) (2008). Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil. Annals of Oncology. 1154-1159.
  • Vis forfatter(e) (2008). A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Annals of Oncology. 909-914.
  • Vis forfatter(e) (2005). SSucralfate does not ameliorate acute radiation proctitis: Randomised study and meta-analysis. Clinical Oncology. 485-491.
  • Vis forfatter(e) (2004). Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncologica. 495-498.
  • Vis forfatter(e) (2004). Multicentre phase II study of Nordic 5-fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology. 31-38.
  • Vis forfatter(e) (2003). Profiles and time course of acute radiation toxicity symptoms during conformal radiotherapy for cancer of the prostate. Acta Oncologica. 741-748.
  • Vis forfatter(e) (2003). Nordic 5-Fluorouracil/Leucovorin bolus schedule combined with Oxaliplatin (Nordic FLOX)as first-line treatment of metastatic colorectal cancer. Acta Oncologica. 827-831.
  • Vis forfatter(e) (2003). Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to Oxaliplatin combination chemotherapy: Implications for tumor marker monitoring and guidelines. Journal of Clinical Oncology. 4466-4467.
  • Vis forfatter(e) (2002). Ulceration as a possible link between duodenogastric reflux and neoplasms in the stomach of rats. Journal of Surgical Research. 167-178.
  • Vis forfatter(e) (2002). Gastric mucosa lesions induced by duodenogastric reflux increase the penetration of N-[3H]-methyl-N-nitro-N-nitrosoguanidine into the corpus mucosa of rats. Digestive Diseases and Sciences. 2354-2369.
  • Vis forfatter(e) (2002). Duodenogastric reflux increases the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the antral mucosa of rats. A possible role for mucosal erosions and increased cell proliferation in gastric carsinogenesis. Japanese Journal of Cancer Research. 484-494.
  • Vis forfatter(e) (2001). Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and hemolysis. Case report. Acta Oncologica. 882-883.
  • Vis forfatter(e) (1999). Glutathione modulation changes the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the gastric mucosa of rats. Digestive Diseases and Sciences. 2063-2075.
  • Vis forfatter(e) (1998). Lymphocele after retroperitoneal surgery for testicular or extragonadal germ cell tumors may mimic recurrence. Urology. 833-834.
  • Vis forfatter(e) (1998). Lymphocele after retroperitoneal surgery for testicular or extragonadal germ cell tumors may mimic recurrence. Urology. 833-834.
  • Vis forfatter(e) (1998). Effect of gastric secretion on the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the gastric mucosa of rats. Digestive Diseases and Sciences. 2012-2020.
  • Vis forfatter(e) (1997). Glutathione and N-acetylcysteine reduce gastric mucosal blood flow in rats. Digestive Diseases and Sciences. 1765-1774.
  • Vis forfatter(e) (1993). Gastric mucosal injury and associated changes in mucosal blood flow and gastric fluid secretion caused by dimethyl sulphoxide (DMSO) in rats. Digestive Diseases and Sciences. 1243-1250.
Rapport
  • Vis forfatter(e) (2007). Health economic evaluation of bevacizumab for metastatic colorectal cancer. 23/2007. 23/2007. .
Vitenskapelig foredrag
  • Vis forfatter(e) (2015). Modell for å beregne overlevelse og kostnader av behandling for kolorektal cancer.
  • Vis forfatter(e) (2005). A randomised phase III multicenter trial comparing irinotecan in combination with 5FU and folinic acid (FU/FA) given according to the Nordic bolus schedule to irinotecan in combination with 5FU/FA given according to the bolus/infused de Gramont schedule, in patients with metastatic colorectal cancer.
Leder
  • Vis forfatter(e) (2012). Palliative chemotherapy in elderly patients with metastatic colorectal cancer: Do we know how it should be used? Acta Oncologica. 819-821.
Leserinnlegg
  • Vis forfatter(e) (2019). Ekspertpanel for ny vurdering ved alvorlig sykdom. Tidsskrift for Den norske legeforening. 2 sider.
Short communication
  • Vis forfatter(e) (2008). Surgery vs surgery and chemotherapy for colorectal liver metastases. The Lancet. 203.
Doktorgradsavhandling
  • Vis forfatter(e) (1994). Penetration of carcinogens into normal and damaged gastric mucosa.
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • Vis forfatter(e) (2014). Recurrence Patterns After Resection of Liver Metastases from Colorectal Cancer. 10 sider.
  • Vis forfatter(e) (2013). Ultrasound-assisted treatment of an inoperable pancreatic cancer. 4 sider.
  • Vis forfatter(e) (2009). Endokrine svulster. 9 sider.
  • Vis forfatter(e) (2008). The use of Chemotherapy for Neuroendocrine Tumors. 6 sider.
  • Vis forfatter(e) (1999). Antimetabolitter. 20 sider.
Sammendrag/abstract
  • Vis forfatter(e) (2021). Molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. Annals of Oncology. S910-S911.
  • Vis forfatter(e) (2021). Folfirinox in the treatment of advanced gastroenteropancreatic neuroendocrine carcinomas. Annals of Oncology. 915-915.
  • Vis forfatter(e) (2019). Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results. Annals of Oncology. iv131-iv131.
  • Vis forfatter(e) (2018). Total circulating cell-free DNA (cfDNA) as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy. Annals of Oncology. v109-v109.
  • Vis forfatter(e) (2016). Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma. Journal of Clinical Oncology.
  • Vis forfatter(e) (2013). Ki-67 Proliferative Index Predicts Response to Chemotherapy and Survival in 252 Patients with High-Grade Gastrointestinal Neuroendocrine Carcinoma (WHO G3). Pancreas. 382-382.
  • Vis forfatter(e) (2012). Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal poorly differentiated neuroendocrine carcinoma: The NORDIC NEC study. Journal of Clinical Oncology. 1 sider.
  • Vis forfatter(e) (2012). Plasma concentrations of YKL-40 in chemo-naive patients with metastatic colorectal cancer treated with FLOX with or without cetuximab: Results from the NORDIC VII study. Journal of Clinical Oncology. 1 sider.
  • Vis forfatter(e) (2012). Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group. Journal of Clinical Oncology. 1 sider.
  • Vis forfatter(e) (2012). Long term survival data from EORTC Study 40983:perioperative chemotherapy for resectable liver metastasesfrom colorectal cancer. Annals of Oncology. 18-18.
  • Vis forfatter(e) (2012). EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results. Journal of Clinical Oncology. 1 sider.
  • Vis forfatter(e) (2012). AGE DEPENDENT INCREASE IN MEDIAN AND LONG-TERM SURVIVAL IN 29 628 METASTATIC COLORECTAL CANCER (MCRC) SCANDINAVIAN PATIENTS DURING THE PAST TWO DECADES. Annals of Oncology. 188-188.
  • Vis forfatter(e) (2010). Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the Nordic VII study (NCT00145314), by the Nordic colorectal cancer biomodulation group. Annals of Oncology. 9-9.
  • Vis forfatter(e) (2006). Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM). Interim results of EORTC Intergroup randomized phase III study 40983. Journal of Clinical Oncology. 146S-146S.
  • Vis forfatter(e) (2005). Feasibility and risks of pre-operative chemotherapy (CT) with Folfox 4 and surgery for resectable colorectal cancer liver metastases (LM). Interim results of the EORTC Intergroup randomized phase III study 40983. Journal of Clinical Oncology. 253S-253S.
Poster
  • Vis forfatter(e) (2014). Development and validation of a Norwegian model for colorectal cancer.
  • Vis forfatter(e) (2003). Nordic 5-fluorouracil/folinic acid bolus schedule combined with oxaliplatin (FLOX) as first-line treatment to metastatic colorectal cancer.
Errata
  • Vis forfatter(e) (2016). Erratum: Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" (European Journal of Cancer (2016) 68 (208?209) (S0959804916320780) (10.1016/j.ejca.2016.04.010)). European Journal of Cancer. 208-209.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2020). PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Endocrine-Related Cancer. R67-R77.
  • Vis forfatter(e) (2018). Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. European Journal of Cancer. 115-124.
  • Vis forfatter(e) (2016). Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer. European Journal of Cancer. 11-24.
  • Vis forfatter(e) (2014). Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2814-2823.
  • Vis forfatter(e) (2009). Positronemisjonstomografi ved nevroendokrine svulster. Tidsskrift for Den norske legeforening. 1474-1477.
  • Vis forfatter(e) (2008). Palliativ kjemoterapi og strålebehandling ved metastatisk kolorectalkreft. Tidsskrift for Den norske legeforening. 194-197.

Se fullstendig oversikt over publikasjoner i CRIStin.